Human LILRB2/CD85d/ILT4 Protein
Catalog No: LILRB2-HP004
- Species
- Human
- Expression System
- HEK293
- Tag
- an mFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human LILRB2/CD85d/ILT4 Protein is expressed in HEK293 cells with an mFc (IgG1) tag at the C-terminus. It contains amino acid residues Gln22-Arg457 (accession: AAL36991.1).
Product Details
- Molecular Aliases
- CD85d; ILT4; ILT-4; ILT4CD85d; LILRB2; LIR2; MIR10
- Protein Length
- Gln22-Arg457
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 73.6 kDa. Due to glycosylation, the protein migrates to 80-110 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human LILRB2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Human LILRB2, mFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-LILRB2 Antibody, hFc Tag with the EC50 of 5.1ng/ml determined by ELISA (QC Test).
Serial dilutions of Anti-LILRB2 Antibody were added into Human HLA-G Complex Tetramer, His Tag: Human LILRB2, mFc Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 0.11μg/ml.
Background
The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC). LILRB2 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles.
References
- Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.J Clin Invest. 2018;128(12):5647-5662.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.